IFBB Pro Champion Anton Antipov Hosts Podcast with Dr. Brian Mehling

On August 2nd, 2019 IFBB Pro Champion and professional fitness model Anton Antipov hosts the podcast Gee Talks, and recently had Dr. Brian Mehling on as a guest to have a long, wide-ranging discussion about the potential of stem cell science.  

Antipov has received three stem cell treatments from Dr. Mehling, once in the BHI clinic in Bratislava, Slovakia, and twice in the new Montego Bay, Jamaica clinic, and intends to receive more.

BHI Ambassador and PFL Featherweight Champion Lance Palmer endorses stem cell therapy in BHI Jamaica

Lance Palmer is a featherweight MMA champion who credits stem cell treatments from BHI with a greater feeling of better overall health, more energy, and help with the training recovery process.

Mr. Palmer is a former amateur wrestler and current mixed martial arts fighter. He competes for the Professional Fighters League in the Featherweight division.  A four-time NCAA All-American, Mr. Palmer was a member of the Ohio State wrestling team.

PFL Featherweight Champion Lance Palmer

Mr. Palmer recently won a fight on July 25, 2019 at the  Ocean Casino Resort in Atlantic City, New Jersey via unanimous decision, collecting three regular season points. In the second round Palmer faced Luis Rafael Laurentino at PFL 5. He won the fight via third-round TKO and advanced to the playoffs.

Mr. Palmer has said that his successful treatment at the BHI Jamaica, Montego Bay clinic has helped him become a better fighter. He received his first treatment in 2016 and says it helps with the recovery process, preventing injury, and gave him an overall increase in energy.  Mr. Palmer recommends stem cell treatments in general and Dr. Brian Mehling in particular to all other athletes. He describes his experience in the video above.

BHI Therapeutics Jamaica provides access to stem cell therapies to patients who may benefit from these treatments. We engage in collaborative relationships with leading institutions, scientists, and physicians across the globe. We only utilize stem cells from either your own body (autologous) or from umbilical cord donors who have proceeded through a multiple step testing process that ensures stem cell patient safety. We do not use embryonic stem cells, nor will we ever.

BHI Therapeutics Jamaica has US board-certified physicians on staff for your safety. Our Scientific Advisory Board and Ethics Committee oversee the disease-specific protocols to ensure the highest standards of patient safety. BHI Therapeutics Jamaica provides therapies for neurological disorders, autoimmune diseases, and orthopedics conditions.

Click here to view our testimonial with Lance Palmer

BHl Rejuve attends The Europa Games Nutrition & Wellness Expo

BHI Rejuve, a hormone optimization program, exhibited at the Europa Games Nutrition & Wellness Expo in Dallas on June 8-9, 2019. Attendees of the conference include individuals who are eager to learn more about improving their quality of life. More than 8,000 wellness enthusiast and professional bodybuilders, competing for their “International Federation of Body Builders (IFBB)” professional cards, attended the two-day event. 

Representatives from BHI Rejuve presented information on its hormone optimization program and provided awareness regarding the importance of one’s hormone levels and their effect on one’s quality of life. 

The Europa Games Expo has been in existence for more than 10 years with several affiliate conferences held throughout the USA. The conferences attract more than 180,000 people annually. It is one of the very few nutrition and wellness conferences that offers the opportunity to obtain IFBB Pro Cards.  In order to become an IFBB pro, a bodybuilder must first earn an IFBB Pro Card. To accomplish this, a bodybuilder l must win a special showcase where he/she is judged on his/her physique.

This year’s conference brought in more than 300 exhibitors, including BHI Rejuve, 24-hour fitness, Bang Energy, Vitamin Shoppe, Orange Theory, US Army, Hello Fresh, Gold’s Gym, and Spartan. Exhibitors had the opportunity to present their companies, goods, and services to bodybuilders, nutrition fanatics and health enthusiasts from across the country.

To check out our video from the event, click the link below.

Dr. Brian Mehling presents in Monaco

Brian Mehling, MD, and Michael Kelly, MD had a successful presentation at the Princess Grace Hospital Monaco in Monte Carlo, France.

Dr. Brian Mehling’s presentation was focused on BHI Therapeutic Sciences (BHITS) stem cell research studies.

It included BHITS stem cell therapy methods, results of Institutional Review Board approved stem cell research studies, resent advances in BHITS stem cell research (Presentation at the American Academy of Orthopedic Surgeons Annual Meeting, New Orleans, Louisiana, 2018 and Presentation at the conference Adult Stem Cells and Regenerative Medicine. The New York Academy of Sciences, NY, 2019) and information on FDA endorsed Investigational New Drug (IND) application entitled Evaluation of the Safety and Efficacy of HPC, Cord Blood in Subjects With Acute Ischemic Stroke.

Dr. Michael Kelly’s presentation was specifically focused on BHITS follow-on IND application entitled “Evaluation of the Safety and Efficacy of Hematopoietic Progenitor Cells, Cord Blood in Subjects with Knee Osteoarthritis Associated Pain”.

It described the study objectives, inclusion and exclusion criteria, safety and efficacy endpoints.

BHI Therapeutic Sciences at World Bank and International Monetary Fund Annual Meetings in DC

Blue Horizon Charitable Foundation was represented at the World Bank and International Monetary Fund Annual Meetings in DC.
This year’s events took place in Washington, D.C. from October 14-20, 2019.
Katarina Novakova, Director of Relations at Blue Horizon Charitable Foundation attended the meetings on behalf of the organization.
The World Bank Group is one of the world’s largest sources of funding and knowledge for developing countries. Its five institutions share a commitment to reducing poverty, increasing shared prosperity, and promoting sustainable development.
Ms. Novakova said: “Participants were discussing the solutions that can trigger inclusive economic growth, why debt transparency is important, what the workable solutions are to tackle the biodiversity crisis, and what are the actions needed to address the education challenge, especially the number of children who can’t read by the age of ten.”
The program of events showcased unique stories that could help inspire others, such as innovations in creating financial and market opportunities for women entrepreneurs, and how investment and innovation in infrastructure have helped deliver sustainable growth and social development for communities and countries.
To boost action and accelerate progress towards tackling development challenges and reducing extreme poverty, delegates from the member countries, observer organizations, civil society, private sector, and media convened at the 2019 Annual Meetings of the World Bank Group and the International Monetary Fund (IMF).

BHI THERAPEUTIC SCIENCES ABSTRACT TO BE PRESENTED AT GERMAN STEM CELL CONFERENCE

BHI Therapeutic Sciences (BHITS) has been invited to present its abstract, “A retrospective chart review study of allogeneic umbilical cord blood mononuclear cell therapy for stroke,” at the German Stem Cell Network;s 7th Annual GSCN Conference being held Sept. 23-25 at the Max Delbruck Center for Molecular Medicine in Berlin. 

Marina Manvelyan, PhD., BHITS Clinical Research Scientist said: “We are excited to be part of this gathering to share knowledge with other scientists across the globe. We look forward to learning more about what our colleagues are focusing on in stem cell and regenerative therapies.”

The German Stem Cell Network (GSCN) aims to foster basic and applied stem cell research in Germany. The conference will cover the latest findings in stem cell biology in Germany and includes these scientific sessions:
• Pluripotency and reprograming
• Somatic stem cells and development
• Hematopoietic stem cells
• Stem cells in diseases: cancer stem cells
• Stem cells in regenerative therapies
• Stem cells in disease modeling and drug development
• Computational stem cell biology

“Stem cell therapies are, without a doubt, the future of medicine. I believe

they will become the preferred substitutes for many surgical,

pharmacological, and rehabilitative medical services,” 

“The importance of clinical trials and the key direction that it will take will truly

shape the way patients with chronic conditions, disorders, and acute diseases

are treated,” shared Brian Mehling, MD, Chief Medical Officer of BHITS.

BHITS abstract is focused on stroke. Stroke is a leading cause of adult disability worldwide and the second highest cause of death in the world. To date, there are no clinically effective pharmacotherapies that can promote or facilitate cellular functional recovery after an ischemic stroke. Human umbilical cord blood cell therapy is a promising treatment for ischemic stroke. The current retrospective chart review study is aimed to analyze the impact of human umbilical cord blood mononuclear cell therapy on mobility and muscle strength of upper and lower extremities, and neurological function in subjects with ischemic and hemorrhagic stroke.”

Ninety-seven subjects with ischemic and hemorrhagic stroke, treated with human umbilical cord blood mononuclear cells in the Wuhan Hongqiao Brain Hospital Co., Ltd. (Wuhan, Hubei) between March 2009 and March 2012, were included in the retrospective chart review study. Subjects received three administrations of 5 ml human umbilical cord blood mononuclear cells (3×10^8) isolated from human umbilical cord blood of three different donors. Treatment was conducted in three sessions via intravenous and intrathecal administrations. This retrospective chart review study was approved by an Institute of Regenerative and Cellular Medicine Institutional Review Board (IRCM approval number: IRCM-2017-135). All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5).

Analysis of post-stroke physical conditions before and two months after the last human umbilical cord blood mononuclear cell therapy session showed improvement of upper and lower extremity mobility and muscle strength, and neurological function (ability to speak, urinary and bowel function). Significant improvement of upper and lower extremity muscle strength was observed in subjects with ischemic and hemorrhagic stroke, treated with human umbilical cord blood mononuclear cells in two or three intrathecal administrations.

 BHI Therapeutic Sciences is pioneering ethical, effective, safe and affordable stem cell treatment therapies utilizing cord blood stem cells.   Our stem cell products evaluated in clinical studies are collected in accordance with Good Tissue Practice to ensure safety. The studies have been conducted following approval by an Investigational Research Board and in accordance with Good Clinical Practice. Our results show our cellular products are safe and effective in the improvement of symptoms related to chronic inflammation, spinal cord injury, stroke, musculoskeletal disorders and other medical conditions. Multiple studies of umbilical cord blood derived stem cell therapies and adipose-derived stem cell therapies are currently under investigation in clinical trials for a wide-range of medical conditions and show promising results. The Food and Drug Administration (FDA) has given us approval to proceed with our Investigational New Drug (IND) application allowing for the initiation of a clinical study of an FDA-approved cell therapy (HCP, cord blood) for treatment of acute ischemic stroke. For more information, please visit www.bhisciences.com

BHI Therapeutic Sciences studies are registered at the clinical trial registries

Clinical trials are research investigations that play an important role in the development of health information and research for public health care. Clinical trials guiding principles are based on maximum benefit and minimal risk to the participants enrolled in a study.

According to the Ethical Principles for Medical Research Involving Human Subjects (World Medical Association Declaration of Helsinki), “every clinical trial must be registered in a publicly accessible database before recruitment of first subject”. The main registry purpose is to fulfill ethical obligations to participants and the research community and provide information to potential participants and referring clinicians.

BHI Therapeutic Sciences (BHITS) announced the registration of the clinical trial entitled “Evaluation of the Safety and Efficacy of Hemacord HPC, Cord Blood in Subjects with Acute Ischemic Stroke” at the ClinicalTrials.gov registry of clinical trials. Initiation of the clinical study, presented in the Investigator-led IND (Investigational New Drug) application, was endorsed by The Food and Drug Administration (FDA). This is a phase one study investigating the safety and efficacy profile of allogeneic cord blood hematopoietic progenitor cells (HPC, Cord Blood), when administered by intravenous infusion and intrathecal injection, in subjects who have sustained an acute ischemic stroke within the past nine days.

To follow the ethical guidelines in clinical research, BHITS retrospectively registered another clinical study entitled “Retrospective chart review study of umbilical cord stem cell therapy for stroke” at the International Standard Randomised Controlled Trials Number (ISRCTN) registry (Biomed Central, Part of Springer Nature). This retrospective chart review study is aimed to analyze the impact of human umbilical cord blood mononuclear cell therapy on mobility and muscle strength of upper and lower extremities, and neurological function in subjects with ischemic and hemorrhagic stroke.

“Our research is becoming stronger and we are gaining momentum. It is important to show the scientific community and also the general public the promising results of our research. We are strong believers in stem cell therapies, and are working tirelessly on making it available for a wider audience”, said Brian Mehling, MD, CMO of BHITS, and the Principal Investigator of above mentioned clinical trials.

BHI Therapeutic Sciences is pioneering ethical, effective, safe and affordable stem cell treatment therapies utilizing cord blood stem cells.    Our stem cell products evaluated in clinical studies are collected in accordance with Good Tissue Practice to ensure safety. The studies have been conducted following approval by an Investigational Research Board and in accordance with Good Clinical Practice. Our results show our cellular products are safe and effective in the improvement of symptoms related to chronic inflammation, spinal cord injury, stroke, musculoskeletal disorders, and other medical conditions.  Multiple studies of umbilical cord blood-derived stem cell therapies and adipose-derived stem cell therapies are currently under investigation in clinical trials for a wide range of medical conditions and show promising results. For more information, please visit www.bhisciences.com.

ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world. ClinicalTrials.gov is a registry of clinical trials. It is run by the United States National Library of Medicine (NLM) at the National Institutes of Health and is the largest clinical trials database, currently holding registrations from over 230,000 trials from 195 countries in the world. The National Library of Medicine in the National Institutes of Health made ClinicalTrials.gov available to the public via the internet on February 29, 2000.[6] In this initial release, ClinicalTrials.gov primarily included information about NIH-sponsored trials, omitting the majority of clinical trials being performed by private industry. For more information, please visit www.ClinicalTrials.gov.

The ISRCTN registry is a primary clinical trial registry recognized by WHO and ICMJE that accepts all clinical research studies (whether proposed, ongoing or completed), providing content validation and curation and the unique identification number necessary for publication. All study records in the database are freely accessible and searchable. ISRCTN supports transparency in clinical research, helps reduce selective reporting of results and ensures an unbiased and complete evidence base. For more information, please visit www.isrctn.com.

BHI Therapeutic Sciences exhibits at World Congress on Anti-Aging Medicine in Las Vegas

BHI Therapeutic Sciences (BHITS), BHI Rejuve, and Alpha Blu Skin Care participated in the 26th World Congress on Anti-Aging Medicine & Exhibition in Las Vegas, December 13-15, 2018.

Prominent, influential, and notable leaders in healthcare delivered keynote presentations at the 26th Annual World Congress: all of which were focused on the critical need for both innovation and transformation in medicine. The speakers represented the continual effort to redefine and reshape medicine, and inspired attendees to commit and contribute toward a new century of wellness and longevity.

Brian Mehling, M.D., chief medical officer of BHITS was joined by Klara Doert of BHI Germany; Alan Pereira of BHI Brazil; Fidel Desmar, Brandon Pope, and Katarina Novakova of BHITS, USA.

“Blue Horizon Rejuve program is the latest initiative of BHITS. It focuses on rejuvenation and anti-aging of the human body, with the help of a complex of vitamins, hormones and stem cell therapy,” said Dr. Mehling. “The anti-aging part of BHITS activities is only one component. Its program is more complex and offers advanced stem cell therapy to patients worldwide,” he added.

Blue Horizon International Therapeutic Sciences (BHITS) is a healthcare management company with a unique hospital concept that focuses on providing the highest quality care and service available in surgical and medical treatments, as well as utilizing the most advanced technologies currently available in areas such as stem cell research, operating room technology, hospital management, electronic medical records and medical staff training. BHITS bring the finest doctors and surgeons, medical technology, and hospital management from the United States to the rest of the world with the highest level of care. BHITS is the established brand for the international delivery of the highest quality health care available and staffs medical facilities through the extensive network connections of our Board of Directors, Management Team, Advisory Board Members, and growing international affiliations.  BHITS has established working relationships with some of the most prominent and highly ranked hospitals in the United States and around the world, such as BHI Slovakia and BHI Jamaica. This collaborative work allows for rapid development of research protocols, with the aim of eventually developing less expensive treatments for many of today’s illnesses. Accordingly,  BHITS recruits the very best clinicians from around the world. For more information please visit www.bhsciences.com

BHITS also maintains a special emphasis on charitable work, giving back to the local communities. For more information on our charitable work, please  visit www.bluehorizonfoundation.org. 

 The American Academy of Anti-Aging Medicine, Inc. (“A4M”) is a non-profit medical society dedicated to the advancement of technology to detect, prevent, and treat aging related disease and to promote research into methods to optimize the human aging process. A4M is also dedicated to educating physicians, scientists, and members of the public on anti-aging issues.  The disabilities caused by the human aging process are caused by physiological dysfunctions which in most cases are ameliorable to medical treatment, such that the human life span can be increased, and the quality of one’s life improved as one grows chronologically older. A4M intends to spread awareness about innovative science and research, as well as treatment modalities designed to prolong the human life span. The core of anti-aging medicine is based on scientific principles of comprehensive medical care encompassing those of many other specialties within healthcare.

What do Athletes Need to Know about Stem Cell Therapies?

·        Osteoarthritis (OA) is the most common form of arthritis and a major cause of pain and disability in adult individuals. Systemic inflammation observed in OA is partially reflective of local synovial inflammation. Common treatments for OA include agents for control of pain and inflammation, such as non-steroidal anti-inflammatory drugs, analgesics including opioids, locally administered corticosteroids and viscosupplementation.

·        Cellular therapy is an emerging modality for the treatment of OA. Administration of stem cells with anti-inflammatory function may be effective at preventing or delaying OA if delivered at early stages in the disease process. Human umbilical cord stem cell therapy is safe and effective for articular cartilage regeneration in patients with osteoarthritic knees.

·        BHI Therapeutic Sciences is planning to submit an Investigator-led, research only Investigational New Drug (IND) application for the use of FDA-approved cell therapy (Hematopoietic Progenitor Cells (HPC), cord blood) in the treatment of osteoarthritis. This prospective, open-label, single-center, exploratory clinical study will be designed to characterize the safety and efficacy profile of HPC, cord blood, when administered by intra-articular injection and intravenous infusion, in subjects with OA.

·        The application of stem cell therapy in the sports medicine arena has expanded in recent years. Orthobiologics are biological substances that orthopaedic surgeons use to help musculoskeletal injuries heal quicker. More information regarding advantages of Orthobiologiscs in sport regenerative medicine can be found in the article “Orthobiologics: What do Athletes Need to Know about Stem Cell Therapies?”

 

What do Athletes Need to Know about Stem Cell Therapies?